DK2976646T3 - Adrenomedullin til føring af terapi af blodtryksfald - Google Patents
Adrenomedullin til føring af terapi af blodtryksfald Download PDFInfo
- Publication number
- DK2976646T3 DK2976646T3 DK14711741.0T DK14711741T DK2976646T3 DK 2976646 T3 DK2976646 T3 DK 2976646T3 DK 14711741 T DK14711741 T DK 14711741T DK 2976646 T3 DK2976646 T3 DK 2976646T3
- Authority
- DK
- Denmark
- Prior art keywords
- adrenomedulline
- carrying
- blood pressure
- out therapy
- pressure departure
- Prior art date
Links
- 230000036772 blood pressure Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13160265 | 2013-03-20 | ||
| PCT/EP2014/055554 WO2014147153A1 (en) | 2013-03-20 | 2014-03-19 | Adrenomedullin to guide therapy of blood pressure decline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2976646T3 true DK2976646T3 (da) | 2020-11-16 |
Family
ID=47901848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14711741.0T DK2976646T3 (da) | 2013-03-20 | 2014-03-19 | Adrenomedullin til føring af terapi af blodtryksfald |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10598674B2 (da) |
| EP (1) | EP2976646B1 (da) |
| JP (3) | JP6259905B2 (da) |
| CN (2) | CN108362885B (da) |
| CA (1) | CA2907467A1 (da) |
| DK (1) | DK2976646T3 (da) |
| ES (1) | ES2830036T3 (da) |
| HK (2) | HK1216264A1 (da) |
| RU (1) | RU2673455C2 (da) |
| SG (2) | SG11201507774YA (da) |
| WO (1) | WO2014147153A1 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018010269A2 (pt) * | 2015-11-27 | 2019-02-05 | Brahms Gmbh | mr-proadm como marcador para o status do volume extracelular de um indivíduo |
| MX2019000003A (es) * | 2016-07-08 | 2019-08-29 | Sphingotec Gmbh | Adrenomodulina para evaluar la congestión en un individuo con insuficiencia cardiaca aguda. |
| EP3309550A1 (en) * | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| JP6855118B2 (ja) * | 2017-03-14 | 2021-04-07 | 東ソー株式会社 | 全身状態の良不良を評価するための情報を提供する方法及び測定試薬 |
| JP7001285B2 (ja) * | 2017-03-29 | 2022-01-19 | 国立大学法人 宮崎大学 | 長時間作用型アドレノメデュリン誘導体 |
| CN107194129B (zh) * | 2017-06-30 | 2019-08-06 | 江南大学 | 一种应用乳酸修正的adm1模型分析餐厨垃圾产甲烷的方法 |
| EP3438668A1 (en) | 2017-08-04 | 2019-02-06 | B.R.A.H.M.S GmbH | Diagnosis and risk stratification of fungal infections |
| WO2019053124A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | PROADRENOMEDULINE AS AN INDICATOR FOR RENAL REPLACEMENT THERAPY IN SERIOUSLY PATIENT PATIENTS |
| EP4027145A1 (en) * | 2017-09-13 | 2022-07-13 | B.R.A.H.M.S GmbH | Pro-adm for therapy monitoring of intensive care unit patients |
| CN111094986B (zh) * | 2017-09-13 | 2023-11-10 | B.R.A.H.M.S有限公司 | 基于肾上腺髓质素前体的指导流体治疗的方法 |
| EP3971573A1 (en) | 2017-09-13 | 2022-03-23 | B.R.A.H.M.S GmbH | Proadrenomedullin as a marker for abnormal platelet levels |
| CA3076691A1 (en) * | 2017-09-25 | 2019-03-28 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
| US20220268761A1 (en) * | 2017-10-18 | 2022-08-25 | Adrenomed Ag | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder |
| EP3502706A1 (en) * | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
| WO2019122089A1 (en) * | 2017-12-20 | 2019-06-27 | B.R.A.H.M.S Gmbh | Antibiotic therapy guidance based on pro-adm |
| EP3578989A1 (en) * | 2018-06-06 | 2019-12-11 | B.R.A.H.M.S GmbH | Pro-adm for prognosis of trauma-related complications in polytrauma patients |
| JP2022507380A (ja) * | 2018-11-15 | 2022-01-18 | フェリング ベスローテン フェンノートシャップ | 敗血症を治療するための化合物、組成物及び方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8519425D0 (en) | 1985-08-01 | 1985-09-04 | Ici Plc | Amine production |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| EP1427750B1 (en) | 2001-08-30 | 2010-12-08 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| AU2003243394B2 (en) | 2002-06-07 | 2008-06-12 | Takeda Pharmaceutical Company Limited | Prevention and reduction of blood loss |
| DE10316583A1 (de) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| US20050148029A1 (en) * | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
| EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| EP2314308A1 (en) | 2004-09-21 | 2011-04-27 | BioNTech AG | Use of microproteins as tryptase inhibitors |
| AU2006299417A1 (en) * | 2005-10-03 | 2007-04-12 | Biosite Incorporated | Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes |
| US8906857B2 (en) * | 2005-12-01 | 2014-12-09 | B.R.A.H.M.S. Gmbh | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
| DE102006060112A1 (de) * | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM |
| WO2009009907A1 (en) * | 2007-07-18 | 2009-01-22 | The University Of British Columbia | Use of vasopressin-receptor agonists for the treatment of septic shock |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| WO2009150171A1 (en) * | 2008-06-10 | 2009-12-17 | Profos Ag | Method of treatment of inflammatory diseases |
| CN102272148A (zh) | 2008-11-03 | 2011-12-07 | 分子组合公司 | 抑制vegf-a受体相互作用的结合蛋白 |
| AU2010288542B2 (en) | 2009-08-27 | 2014-05-22 | Covagen Ag | IL-17 binding compounds and medical uses thereof |
| EP2379581B1 (en) | 2009-12-14 | 2013-10-09 | Scil Proteins GmbH | A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
| PL2580236T3 (pl) | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Muteiny lipokaliny łez wiążące IL-4 R alfa |
| EP2583106A1 (en) * | 2010-06-18 | 2013-04-24 | Cézanne S.A.S. | Markers for the prognosis and risk assessment of pregnancy-induced hypertension and preeclampsia |
-
2014
- 2014-03-19 ES ES14711741T patent/ES2830036T3/es active Active
- 2014-03-19 SG SG11201507774YA patent/SG11201507774YA/en unknown
- 2014-03-19 EP EP14711741.0A patent/EP2976646B1/en active Active
- 2014-03-19 CA CA2907467A patent/CA2907467A1/en active Pending
- 2014-03-19 CN CN201810035720.XA patent/CN108362885B/zh active Active
- 2014-03-19 RU RU2015144699A patent/RU2673455C2/ru active
- 2014-03-19 SG SG10201800309SA patent/SG10201800309SA/en unknown
- 2014-03-19 CN CN201480010451.1A patent/CN105102985B/zh active Active
- 2014-03-19 DK DK14711741.0T patent/DK2976646T3/da active
- 2014-03-19 JP JP2016504582A patent/JP6259905B2/ja active Active
- 2014-03-19 WO PCT/EP2014/055554 patent/WO2014147153A1/en active Application Filing
- 2014-03-19 US US14/778,114 patent/US10598674B2/en active Active
-
2016
- 2016-04-13 HK HK16104224.2A patent/HK1216264A1/zh unknown
-
2017
- 2017-12-11 JP JP2017236881A patent/JP2018059947A/ja not_active Ceased
-
2019
- 2019-01-17 HK HK19100872.2A patent/HK1258520A1/zh unknown
- 2019-12-25 JP JP2019234773A patent/JP6820399B2/ja active Active
-
2020
- 2020-02-04 US US16/781,226 patent/US20200249246A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN105102985B (zh) | 2018-05-18 |
| US20170010286A1 (en) | 2017-01-12 |
| SG11201507774YA (en) | 2015-10-29 |
| JP2020073896A (ja) | 2020-05-14 |
| HK1258520A1 (zh) | 2019-11-15 |
| EP2976646B1 (en) | 2020-08-19 |
| US10598674B2 (en) | 2020-03-24 |
| EP2976646A1 (en) | 2016-01-27 |
| RU2015144699A (ru) | 2017-04-28 |
| CA2907467A1 (en) | 2014-09-25 |
| CN108362885A (zh) | 2018-08-03 |
| ES2830036T3 (es) | 2021-06-02 |
| JP2018059947A (ja) | 2018-04-12 |
| US20200249246A1 (en) | 2020-08-06 |
| HK1216264A1 (zh) | 2016-10-28 |
| WO2014147153A1 (en) | 2014-09-25 |
| JP6259905B2 (ja) | 2018-01-10 |
| SG10201800309SA (en) | 2018-02-27 |
| CN105102985A (zh) | 2015-11-25 |
| CN108362885B (zh) | 2021-05-14 |
| JP6820399B2 (ja) | 2021-01-27 |
| RU2673455C2 (ru) | 2018-11-27 |
| JP2016521351A (ja) | 2016-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2976646T3 (da) | Adrenomedullin til føring af terapi af blodtryksfald | |
| DK3041926T3 (da) | Indretning til in-vitro-modellering af in-vivo-væv af organer | |
| DK3076967T3 (da) | Fremgangsmåder til behandling af residuelle symptomer på skizofreni | |
| DK3030323T3 (da) | Kdm1a-inhibitorer til behandlingen af sygdom | |
| DK3080100T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3043816T3 (da) | Anti-b7-h1-antistoffer til behandling af tumorer | |
| DK3611262T3 (da) | Fremgangsmåder til sekvensering af immunrepertoire | |
| DK2983787T3 (da) | Fremgangsmåde til behandling af posttraumatisk stresssygdom | |
| DK2895156T3 (da) | Fremgangsmåde til fremstilling af terapeutiske nanopartikler | |
| IL245213A0 (en) | Inhibitors of human immunodeficiency virus replication | |
| DK2906696T4 (da) | Fremgangsmåder til modulering af c9orf72-ekspression | |
| DK3033086T3 (da) | Kombinationsterapi til behandling af cancer | |
| DK3035926T3 (da) | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse | |
| DK3329884T3 (da) | Implanterbar indretning til behandling af glaukom | |
| DK2992908T3 (da) | Fremgangsmåde til overfladebehandling af implantat | |
| DK2964315T3 (da) | System til behandling af neuromotorisk dysfunktion | |
| DK2968208T3 (da) | Behandling af kataplexi | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
| DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
| DK3204398T3 (da) | Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer | |
| DK2953904T3 (da) | Fremgangsmåde til kontrolleret fremstilling af et biocid | |
| DK3010895T3 (da) | Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner | |
| DK2764881T3 (da) | System til medicinsk behandling | |
| DK3007726T3 (da) | Fremgangsmåder til behandling af en tauopati |